Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.55 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.54 |
| ▸ | USP2 | O75604 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31083609 | 1.00 | SLC7A5 (0.55) | SLC7A5GRIA2HSD17B10USP2ALOX15 | |
| SCHEMBL2121998 | 1.00 | SLC7A5 (0.55) | SLC7A5GRIA2HSD17B10USP2ALOX15 | |
| Hydrochloric Acid SCHEMBL16007570 | 0.98 | GRIA2 (0.53) | SLC7A5GRIA2HSD17B10USP2ALOX15 | |
| Hydrochloric Acid SCHEMBL16007571 | 0.98 | GRIA2 (0.53) | SLC7A5GRIA2HSD17B10USP2ALOX15 | |
| SCHEMBL3523032 | 0.89 | SIRT5 (0.51) | SLC7A5GRIA2HSD17B10USP2ALOX15 | |
| SCHEMBL10667474 | 0.89 | THRB (0.52) | SLC7A5GRIA2HSD17B10USP2ALOX15 | |
| SCHEMBL15085642 | 0.89 | GRIA2 (0.49) | SLC7A5GRIA2HSD17B10USP2ALOX15 | |
| SCHEMBL3523029 | 0.89 | SIRT5 (0.51) | SLC7A5GRIA2HSD17B10USP2ALOX15 | |
| SCHEMBL26378959 | 0.89 | SIRT5 (0.51) | SLC7A5GRIA2HSD17B10USP2ALOX15 | |
| SCHEMBL10667480 | 0.89 | THRB (0.52) | SLC7A5GRIA2HSD17B10USP2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105420203-B | Tyrosine analogue translation system and gene-encoded protein photoinduced electron transfer fluorescence sensor protein family | 中国科学院生物物理研究所 | 2018-11-16 | — | — | CN | claimed |
| CN-105420203-A | Tyrosine analogue translation system and gene-encoded protein photoinduced electron transfer fluorescence sensor protein family | INST OF BIOPHYSICS CHINESE ACAD OF SCIENCES | 2016-03-23 | — | — | CN | claimed |
| EP-2630161-A1 | COMPOSITIONS, ANTIBODIES, ASTHMA DIAGNOSIS METHODS, AND METHODS FOR PREPARING ANTIBODIES | Battelle Memorial Institute (US) | 2013-08-28 | — | — | EP | claimed |
| WO-2012141737-A1 | COMPOSITIONS, ANTIBODIES, ASTHMA DIAGNOSIS METHODS, AND METHODS FOR PREPARING ANTIBODIES | BATTELLE MEMORIAL INSTITUTE (US) | 2012-10-18 | — | — | WO | claimed |
| US-20120094860-A1 | Compositions, Antibodies, Asthma Diagnosis Methods, and Methods for Preparing Antibodies | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-04-19 | — | — | US | claimed |
| EP-4673162-A1 | PATHOGEN-SPECIFIC PEPTIDE TO BLOCK VIRULENCE-RELATED SIGNALING IN CANDIDA ALBICANS | I3S - Instituto de Investigação e Inovação em Saúde, Associação (PT) | 2026-01-07 | — | — | EP | disclosed |
| EP-4653014-A1 | BILIARY TRACT CANCER TREATMENT AGENT | J-Pharma Co., Ltd. (JP) | 2025-11-26 | — | — | EP | disclosed |
| CN-120005847-A | Alpha-hydroxy-beta-keto acid synthase for catalyzing alpha-keto acid coupling reaction | 北京大学 | 2025-05-16 | — | — | CN | disclosed |
| WO-2025079064-A1 | INTERLEUKIN-17 PEPTIDOMIMETIC INHIBITORS | PEPTICOM LTD. (IL) | 2025-04-17 | — | — | WO | disclosed |
| US-20250041281-A1 | METHOD OF TREATING BILIARY TRACT CANCER | J-PHARMA CO., LTD. (JP) | 2025-02-06 | — | — | US | disclosed |
| WO-2024181880-A1 | PATHOGEN-SPECIFIC PEPTIDE TO BLOCK VIRULENCE-RELATED SIGNALING IN CANDIDA ALBICANS | I3S - INSTITUTO DE INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE, ASSOCIAÇÃO (PT) | 2024-09-06 | — | — | WO | disclosed |
| US-20230313245-A1 | Engineered Enzymes and Method for the Synthesis of Diverse Tyrosine Analogs | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-10-05 | — | — | US | disclosed |
| US-5061798-A | Intermediates in the formation of synthetic hormones, mimic effects of thyroid hormones; little or no effect on the heart | SMITH KLINE & FRENCH LABORATORIES, LTD. (GB) | 1991-10-29 | — | — | US | disclosed |
| EP-0188351-B1 | CHEMICAL COMPOUNDS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1991-03-13 | — | — | EP | disclosed |
| CN-1010310-B | Preparation method of anti-hyperlipidemia agent | SMITH KLINE FRENCH LAB (GB) | 1990-11-07 | — | — | CN | disclosed |
| US-4910305-A | Containing a protected 4-hydroxyphenyl | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-03-20 | — | — | US | disclosed |
| US-4826876-A | WITHOUT EFFECT ON HEART | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-05-02 | — | — | US | disclosed |
| US-4766121-A | NOT AFFECTING THE HEART | SMITH KLINE & FRENCH LABORATORIES LTD. (GB) | 1988-08-23 | — | — | US | disclosed |
| CN-86100894-A | Process for the preparation of compounds | — | 1986-09-03 | — | — | CN | disclosed |
| EP-0188351-A2 | Chemical compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041281-A1 | METHOD OF TREATING BILIARY TRACT CANCER | ACAT2, NAT1, NAT10 | SLC7A5 679/4885GRIA2 2379/4885HSD17B10 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.